Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2017

View Archived Issues

Fortress Biotech launches subsidiary Cyprium Therapeutics

National Institutes of Health awards SBIR phase II grant to TherapyXinc

Bellicum initiates phase I study of BPX-701 in relapsed or refractory myeloid neoplasms

Acceleron plans phase II trial of ACE-83 in Charcot-Marie-Tooth disease

Medicenna collaborates with MD Anderson on fusion protein therapeutics targeting IL4R

Aerpio Pharmaceuticals completes reverse merger

25-hydroxycholesterol protects against ZIKV-induced microcephaly in vivo

Tempus and University of Chicago establish collaboration in breast cancer

Bumetanide improves symptoms of autism; Servier and Neurochlore to collaborate on treatment

PTC Therapeutics to acquire Emflaza for the treatment of Duchenne muscular dystrophy in U.S.

Theralase demonstrates 18-month stability of its next-generation anticancer PDC, TLD-1433

Momotaro-Gene raises funding to support development of Ad-SGE-REIC

Clinigen partners with Diurnal to launch European managed access program for Infacort and Chronocort

Provecs, Medac and Cevec establish adenoviral vector collaboration in oncology

FDA issues complete response letter for ZS-9 for hyperkalemia

23-gene signature distinguishes malignant melanoma from benign nevi

New trial to combine Reolysin with Imnovid or Revlimid in patients with relapsing myeloma

Bioequivalence demonstrated for gemigliptin/rosuvastatin FDC and individual drugs

BIO-FLARE collaboration explores biological factors that trigger flares in rheumatoid arthritis

Chinese funding supports PegBio's development of GLP-1 analogue PB-119

Bristol-Myers Squibb patents activin receptor-like kinase 5 inhibitors

Arbutus licenses LNP technology to Alexion for use in rare disease program

Auckland Uniservices discloses new IDO and/or TDO inhibitors

Circassia reaches agreement with AstraZeneca on U.S. commercial rights for Tudorza and Duaklir

Incyte Corp discovers TAM kinases inhibitors

Taiho Pharmaceutical presents HER2 inhibitors

Actelion Pharmaceuticals discovers antibacterial annulated pyrrolidin-2-one derivatives

Jiangsu Hansoh Pharmaceutical Group, Shanghai Hansoh Biomedical present angiotensin AT2 antagonists

Bellus Health to sell Thallion Pharmaceuticals subsidiary to Taro

Genentech and Xenon Pharmaceuticals develop Nav1.7 channel blockers

Sunshine Lake Pharma identifies urate transporter 1/xanthine oxidase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...